Bicara Therapeutics Inc. (BCAX) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$9.19

From 52W high−70.76%

Volume1.01M

Market cap$588.28M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$9.19

From 52W high

−70.76%

Volume

1.01M

Market cap

$588.28M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.5x

P/E (TTM)

—

RSI (14)

22.3

MomentumView details →

1D Return

−0.78%

YTD Return

−47.45%

SummaryUpdated Jun 1, 2026

Bicara Therapeutics Inc. (NASDAQ:BCAX) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Boston, Massachusetts. The company operates as a subsidiary of Biocon Limited, a major Indian biopharmaceutical company. Bicara focuses on developing innovative bifunctional antibody therapies specifically designed to treat solid tumors, representing a novel approach in cancer treatment that combines two therapeutic mechanisms into a single drug molecule.

Ask drillr about Bicara Therapeutics Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.5x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−39.54%

ROA (TTM)

−36.19%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−64.89%

FCF YoY

−33.90%

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

−66.21%

MomentumView details →

1D Return

−0.78%

YTD Return

−47.45%

1Y Return

−37.46%

RSI (14)

22.3

vs 50D SMA

−52.99%

vs 200D SMA

−58.06%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

11.59x

Quick Ratio

11.59x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.82

EPS Surprise

−0.03%

Beats (12Q)

2/12

Next Q EPS Est

−$0.86

Avg Surprise (4Q)

0.85%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−185.36M

Op. CF (TTM)

−134.85M

Next earningsNov 9, 2026 →

Latest newsMore news →

Bicara Therapeutics initiated the FORTIFI-FLEX trial, a pivotal Phase III study, and outlined an interim analysis timeline for mid-2027.85d ago

Similar companies

DiaMedica Therapeutics Inc.DMAC Nuvectis Pharma, Inc.NVCT aTyr Pharma, Inc.ATYR Adlai Nortye Ltd.ANL SL Science Holding Limited Ordinary SharesSLBT DBV Technologies S.A.DBVT Find similar companies →

Latest newsMore news →

Bicara Therapeutics Inc. announced that it will report its third-quarter 2026 financial results and business updates before the market opens on November 9, 2026, and host a conference call at 8:30 a.m. ET that day.2d ago Bicara Therapeutics initiated the FORTIFI-FLEX trial, a pivotal Phase III study, and outlined an interim analysis timeline for mid-2027.85d ago